Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $2.85 in the prior trading day, Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $2.94, up 3.16%. In other words, the price has increased by $3.16 from its previous closing price. On the day, 5.36 million shares were traded. ESPR stock price reached its highest trading level at $2.995 during the session, while it also had its lowest trading level at $2.77.
Ratios:
Our goal is to gain a better understanding of ESPR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 17 ’25 when Looker Benjamin bought 1,248 shares for $2.62 per share.
Looker Benjamin sold 6,267 shares of ESPR for $17,573 on Sep 17 ’25. The General Counsel now owns 393,670 shares after completing the transaction at $2.80 per share. On Sep 17 ’25, another insider, Koenig Sheldon L., who serves as the President and CEO of the company, sold 28,427 shares for $2.79 each. As a result, the insider received 79,254 and left with 1,518,831 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 680971136 and an Enterprise Value of 1104888064. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.54. Its current Enterprise Value per Revenue stands at 4.121 whereas that against EBITDA is -31.264.
Stock Price History:
The Beta on a monthly basis for ESPR is 1.04, which has changed by 0.35071087 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 9.10%, while the 200-Day Moving Average is calculated to be 71.36%.
Shares Statistics:
The stock has traded on average 6.69M shares per day over the past 3-months and 4992510 shares per day over the last 10 days, according to various share statistics. A total of 231.62M shares are outstanding, with a floating share count of 226.57M. Insiders hold about 2.18% of the company’s shares, while institutions hold 51.59% stake in the company. Shares short for ESPR as of 1760486400 were 24416434 with a Short Ratio of 3.65, compared to 1757894400 on 24801814. Therefore, it implies a Short% of Shares Outstanding of 24416434 and a Short% of Float of 10.58.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Esperion Therapeutics Inc (ESPR).The consensus estimate for the next quarter is $0.27, with high estimates of $0.62 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.01, with 6.0 analysts recommending between $0.35 and -$0.28.
Revenue Estimates
7 analysts predict $77.8M in revenue for. The current quarter. It ranges from a high estimate of $96.7M to a low estimate of $58.7M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $51.63MFor the next quarter, 7 analysts are estimating revenue of $147.32M. There is a high estimate of $210.2M for the next quarter, whereas the lowest estimate is $65.3M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $439.4M, while the lowest revenue estimate was $227.69M, resulting in an average revenue estimate of $372.31M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $344.62M in the next fiscal year. The high estimate is $396.8M and the low estimate is $263.6M.
